Amphastar Pharmaceuticals, Inc. $AMPH Position Raised by Systematic Financial Management LP

Key Points

• Systematic Financial Management LP increased its stake in Amphastar Pharmaceuticals by 32.6%, owning a total of 326,546 shares valued at approximately $9.47 million.
• Analysts have mixed ratings for Amphastar, with two analysts giving a Buy rating and two maintaining a Hold rating, resulting in a consensus rating of "Moderate Buy" with an average price target of $31.50.
• Amphastar's stock price increased to $30.50, with a current PE ratio of 11.42 and a market cap of $1.42 billion, reflecting its steady performance despite market fluctuations.

Systematic Financial Management LP raised its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 32.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 326,546 shares of the company's stock after purchasing an additional 80,198 shares during the period. Systematic Financial Management LP owned 0.69% of Amphastar Pharmaceuticals worth $9,467,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. TD Asset Management Inc boosted its holdings in shares of Amphastar Pharmaceuticals by 20.2% in the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after buying an additional 371,856 shares during the period. Royce & Associates LP lifted its position in Amphastar Pharmaceuticals by 2,684.3% during the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company's stock valued at $7,185,000 after purchasing an additional 238,956 shares during the period. Boston Trust Walden Corp raised its position in shares of Amphastar Pharmaceuticals by 24.2% in the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock valued at $35,241,000 after acquiring an additional 236,704 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company's stock worth $36,632,000 after acquiring an additional 130,672 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after buying an additional 105,288 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH traded up $0.15 during mid-day trading on Wednesday, hitting $30.49. 326,043 shares of the company's stock were exchanged, compared to its average volume of 574,421. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $1.42 billion, a P/E ratio of 11.42 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96. The business's 50 day moving average is $24.38 and its two-hundred day moving average is $25.82.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AMPH shares. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research note on Friday, August 8th. Wells Fargo & Company decreased their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Bank of America upped their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday. Finally, Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target for the company in a research note on Tuesday, August 12th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.